Company Overview and News

 
Nik Norzul Thani takes over as chairman of Pengurusan Aset Air Berhad

2018-10-03 malaymail
KUALA LUMPUR, Oct 3 — Former Al Rajhi Bank Malaysia chairman Datuk Seri Nik Norzrul Thani is now the chairman of Pengurusan Aset Air Berhad (PAAB).
4588 1058 5272

 
Tokio Marine still discussing sale of stake in M’sian unit

2018-09-03 thestar.com.my
Tokio Marine Life Insurance Malaysia Bhd CEO Toi See Jong(pic) told StarBiz at this juncture its parent was having a board management discussion on the matter. “We are still in discussion and do not have any comment at this moment,” he said when asked whether a potential buyer has been identified for the proposed sale of a stake in Tokio Marine Life Insurance Malaysia.
TKOMF ALIZF GEHDF 1163 AAIGF 1058 AAGIY 8766 GEHDY TKOMY AZSEY BSMAF 1818

 
Foreign insurers given more flexibility to divest their stakes, deadline to depend on bilateral pact

2018-08-17 theedgemarkets
KUALA LUMPUR (Aug 17): Foreign insurers in Malaysia will be given more flexibility to divest their stakes, and the deadline for the divestments will now depend on the bilateral agreement between the insurance companies and Bank Negara Malaysia (BNM).
1058 ALIZF AZSEY 1163 BSMAF 1818

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...